Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Administers its first in-human dose of HG-CT-1, the firm's proprietary CAR-T cell therapy, used in the treatment of relapsed or refractory acute myeloid leukemia in adults. Says further updates on the clinical trial will be provided "in due course".
Co-Founder & Chief Executive Officer Vladislav Sandler says: "We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML."
Current stock price: 356.65 pence, up 12% in London on Monday morning
12-month change: down 70%
By Emily Parsons, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Hemogenyx (HEMO)
